Sanofi, Principia agree to develop multiple sclerosis drug candidate
2017年11月9日 - 09:00PM
Sanofi, Principia agree to develop
multiple sclerosis drug candidate Clinical-stage oral drug
candidate (PRN2246) with the potential to treat multiple sclerosis
Principia to receive $40 million upfront payment, future milestone
payments could total $765 million Paris, France and South San
Francisco, Calif - November 9, 2017 - Sanofi will develop
Principia Biopharma Inc.'s experimental oral treatment that shows
promise in multiple sclerosis (MS) and, potentially, other central
nervous system (CNS) diseases. Under the license agreement signed
this week, Sanofi will develop Principia's Bruton's tyrosine kinase
(BTK) inhibitor (PRN2246), which was designed to access the brain
and spinal cord by crossing the blood-brain barrier and impact
immune cell and brain cell signalling. PRN2246 is currently in
clinical development. "Our agreement with Principia is an example
of Sanofi's strategic commitment to build our drug discovery and
development pipeline in MS and neurological diseases," says Rita
Balice-Gordon, PhD, Global Head of MS/Neuroscience Therapeutic
Research Area at Sanofi. "Complementing our own internal R&D
expertise, external relationships like this may accelerate delivery
of new treatments to patients living with these serious diseases."
"Sanofi is an ideal partner for PRN2246. The agreement allows
Principia to maximize the BTK opportunity in neurology with a
strong partner for PRN2246 while focusing internal resources on our
lead BTK inhibitor in another therapeutic area," said Martin
Babler, Chief Executive Officer of Principia Biopharma. "PRN2246 is
a blood brain barrier crossing, highly potent BTK inhibitor, that
we believe is especially well suited for the treatment of MS and
other neurological disorders." Sanofi to receive exclusive,
worldwide licenseUnder the terms of the agreement, Principia
will grant Sanofi an exclusive, worldwide license to develop and
commercialize PRN2246. Sanofi will pay Principia a $40 million
upfront payment, future milestone payments that could total $765
million and royalties on product sales. Principia has the option to
co-fund Phase 3 development, in exchange for either increased
royalties on worldwide product sales or a profit and loss sharing
arrangement in the United States. The transaction is expected to
close in the fourth quarter of 2017, subject to customary
regulatory approvals. Sanofi is a leader in MSSanofi
Genzyme, the specialty care global business unit of Sanofi,
currently has two marketed MS medicines available around the world,
and programs in research and development to address MS, potentially
through neuroprotection and remyelination in addition to
anti-inflammatory mechanisms. Sanofi is committed to discovering
and developing new treatment options for people living with MS.
About Principia BiopharmaPrincipia Biopharma Inc., a
private, clinical-stage biopharmaceutical company, has created a
revolutionary new way to design and develop oral small molecule
therapies that are more potent, selective, durable and safer than
currently available drugs. The Company has utilized its
proprietary Tailored Covalency(TM) technology to develop a
portfolio of drug candidates that exhibit antibody-like specificity
to benefit patients with autoimmune and inflammatory diseases and
cancer. PRN1008, a reversible covalent BTK inhibitor, is
currently being evaluated in a Phase 2 clinical trial in patients
with pemphigus, an orphan autoimmune disease. PRN1371, a
covalent FGFR1-4 inhibitor, is currently being evaluated in a Phase
1 clinical trial in cancer patients with various solid
tumors. PRN2246, a low dose covalent BTK inhibitor which
crosses the blood brain barrier, recently has initiated a Phase 1
clinical trial in healthy volunteers. For more information,
please visit the Company's website at www.principiabio.com.
|
|
About Sanofi Sanofi is dedicated to supporting
people through their health challenges. We are a global
biopharmaceutical company focused on human health. We prevent
illness with vaccines, provide innovative treatments to fight pain
and ease suffering. We stand by the few who suffer from rare
diseases and the millions with long-term chronic conditions. With
more than 100,000 people in 100 countries, Sanofi is transforming
scientific innovation into healthcare solutions around the globe.
Sanofi, Empowering Life |
|
Sanofi Media Relations Contact Jack Cox Tel.: +33 (0)1 53 77
46 46 mr@sanofi.com |
Sanofi Investor Relations Contact George Grofik Tel.: +33
(0)1 53 77 45 45 ir@sanofi.com |
|
Principia Media Contact: Kelly Boothe Pure Communications
Tel: +1 (415) 946-1076
kboothe@purecommunications.com |
Principia Investor Contact: Christopher Chai, Principia Tel:
+1 (650) 416-7730 |
|
Sanofi Forward-Looking StatementsThis press
release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical
facts. These statements include projections and estimates regarding
the clinical development of and potential marketing approvals for
the product. Forward-looking statements are generally identified by
the words "expects", "anticipates", "believes", "intends",
"estimates", "plans", "would be" and similar expressions. Although
Sanofi's management believes that the expectations reflected in
such forward-looking statements are reasonable, investors are
cautioned that forward-looking information and statements are
subject to various risks and uncertainties, many of which are
difficult to predict and generally beyond the control of Sanofi,
that could cause actual results and developments to differ
materially from those expressed in, or implied or projected by, the
forward-looking information and statements. These risks and
uncertainties include among other things, the uncertainties
inherent in research and development of the product, future
clinical data and analysis, including post marketing, decisions by
regulatory authorities, such as the FDA or the EMA, regarding
whether and when to approve the product or biological application
that may be filed for the product as well as their decisions
regarding labeling and other matters that could affect the
availability or commercial potential of the product, the absence of
guarantee that the product if approved will be commercially
successful, risks associated with intellectual property, future
litigation, the future approval and commercial success of
therapeutic alternatives, and volatile economic conditions, as well
as those risks discussed or identified in the public filings with
the SEC and the AMF made by Sanofi, including those listed under
"Risk Factors" and "Cautionary Statement Regarding Forward-Looking
Statements" in Sanofi's annual report on Form 20-F for the year
ended December 31, 2016. Other than as required by applicable law,
Sanofi does not undertake any obligation to update or revise any
forward-looking information or statements. |
|
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/0085b481-38eb-4405-85da-c0311d50ccfd
Sanofi (EU:SAN)
過去 株価チャート
から 2 2024 まで 3 2024
Sanofi (EU:SAN)
過去 株価チャート
から 3 2023 まで 3 2024